GC
AUPH icon

Guggenheim Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Guggenheim Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Buy
+10,279
New +$164K ﹤0.01% 1662

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Guggenheim Capital's AUPH Position: Q2 2026 in Review

Guggenheim Capital opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 10,279 shares worth $174K. The stake represents ﹤0.01% of the portfolio and ranks #1662 among its holdings.

281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Guggenheim Capital held 10,279 shares of Aurinia Pharmaceuticals worth $174K as of Q2 2026.
  • Aurinia Pharmaceuticals was a new Guggenheim Capital position in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1662 holding.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.